Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07118215 · ClinicalTrials.gov registry record · Phase 1

A Study to Evaluate the Effects of KarXT on the Drug Levels of Midazolam, Fexofenadine, and Digoxin

A Phase 1 study of Healthy Volunteers, sponsored by Karuna Therapeutics.

Recruiting
Registry status
Phase 1
Development phase
60
Enrollment target
1
Study location

NCT07118215 is a Phase 1 study of Healthy Volunteers that is actively recruiting participants, run by Karuna Therapeutics. The registered enrollment target is 60 participants, below the 482-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07118215, a Phase 1 study of Healthy Volunteers, is actively recruiting participants, sponsored by Karuna Therapeutics.

RECRUITING
Registry status
Phase 1
Development phase
60 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to evaluate the effects of KarXT administration on the drug levels of midazolam, fexofenadine, and digoxin in healthy adult participants.

Conditions Studied

Interventions

  • DRUG Midazolam
  • DRUG KarXT
  • DRUG Digoxin
  • DRUG Fexofenadine

Study Locations (1)

Kansas

  • ICON - Lenexa - Lenexa

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2025-09-29
Est. Completion 2026-04-05
Phase Phase 1

Sponsor

Karuna Therapeutics

11 total trials

What the Registry Record Tells You About NCT07118215

The ClinicalTrials.gov registry entry for NCT07118215 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 482-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (88% lower). The listed sponsor is Karuna Therapeutics, which has 11 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy Volunteers appearing as the primary indexed condition, and to 4 interventions - of which Midazolam is the first listed.

NCT07118215 reports 1 study location spanning 1 distinct geographic area - top geographies include Kansas.

Frequently Asked Questions

What is clinical trial NCT07118215 about?

NCT07118215 is a clinical study titled "A Study to Evaluate the Effects of KarXT on the Drug Levels of Midazolam, Fexofenadine, and Digoxin". The purpose of this study is to evaluate the effects of KarXT administration on the drug levels of midazolam, fexofenadine, and digoxin in healthy adult participants.

What is the current status of trial NCT07118215?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2025-09-29. Estimated completion is 2026-04-05.

What conditions does trial NCT07118215 study?

This clinical trial studies the following conditions: Healthy Volunteers.

What interventions are being tested in trial NCT07118215?

The interventions under investigation include: Midazolam (DRUG), KarXT (DRUG), Digoxin (DRUG), Fexofenadine (DRUG).

Who is sponsoring clinical trial NCT07118215?

This trial is sponsored by Karuna Therapeutics, which has 11 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07118215 being conducted?

This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Volunteers

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.